DEXRAZOXANE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Dexrazoxane Hydrochloride patents expire, and what generic alternatives are available?
Dexrazoxane Hydrochloride is a drug marketed by Eugia Pharma, Gland, and Hikma. and is included in three NDAs.
The generic ingredient in DEXRAZOXANE HYDROCHLORIDE is dexrazoxane hydrochloride. There are six drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the dexrazoxane hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Dexrazoxane Hydrochloride
A generic version of DEXRAZOXANE HYDROCHLORIDE was approved as dexrazoxane hydrochloride by HIKMA on September 28th, 2004.
Summary for DEXRAZOXANE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 3 |
NDAs: | 3 |
Finished Product Suppliers / Packagers: | 7 |
Raw Ingredient (Bulk) Api Vendors: | 68 |
Clinical Trials: | 57 |
Patent Applications: | 393 |
Formulation / Manufacturing: | see details |
DailyMed Link: | DEXRAZOXANE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for DEXRAZOXANE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Polish Medical Research Agency | Phase 3 |
Maria Sklodowska-Curie National Research Institute of Oncology | Phase 3 |
University of Colorado, Denver | Phase 1 |
Pharmacology for DEXRAZOXANE HYDROCHLORIDE
Drug Class | Cytoprotective Agent |